COYA logo

COYA
Coya Therapeutics Inc

1,144
Mkt Cap
$108.37M
Volume
69,735.00
52W High
$7.75
52W Low
$3.71
PE Ratio
-4.27
COYA Fundamentals
Price
$4.87
Prev Close
$4.62
Open
$4.70
50D MA
$4.36
Beta
1.10
Avg. Volume
151,735.90
EPS (Annual)
-$1.27
P/B
2.21
Rev/Employee
$993,219.13
$50.21
Loading...
Loading...
News
all
press releases
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative...
Business Wire·9d ago
News Placeholder
More News
News Placeholder
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·9d ago
News Placeholder
Coya Therapeutics (COYA) Expected to Announce Earnings on Tuesday
Coya Therapeutics (NASDAQ:COYA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat·16d ago
News Placeholder
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recomme...
MarketBeat·1mo ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen raised Coya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·1mo ago
News Placeholder
Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Friday...
MarketBeat·1mo ago
News Placeholder
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research...
Business Wire·1mo ago
News Placeholder
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative...
Business Wire·2mo ago
News Placeholder
What is HC Wainwright's Estimate for COYA Q1 Earnings?
Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Coya Therapeutics in a note issued to investors...
MarketBeat·2mo ago
News Placeholder
Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Monday...
MarketBeat·2mo ago
<
1
2
...
>

Latest COYA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.